Hydroxyurea therapy is the most feasible disease-modifying treatment for SCA in Africa, with proven clinical benefits for vaso-occlusive pain episodes, acute chest syndrome/pneumonia, malaria, transfusions, hospitalizations, and primary and secondary stroke prevention